BEAUTIFUL TRIAL IVABRADINE PDF

Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Results: A total of 10, patients were randomized. Conclusions: Main results from BEAUTIFUL are expected in , and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.

Author:Mazshura Mikazil
Country:Turkmenistan
Language:English (Spanish)
Genre:Software
Published (Last):7 August 2017
Pages:289
PDF File Size:19.51 Mb
ePub File Size:18.41 Mb
ISBN:509-6-26998-810-5
Downloads:78924
Price:Free* [*Free Regsitration Required]
Uploader:Gashakar



No account yet? Start here. Munich, Germany, 31 August, The results of the much awaited BEAUTIFUL morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction trial have shown that coronary artery disease CAD patients with left ventricular dysfunction LVD and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients heart rate above 70 bpm treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.

With the BEAUTIFUL results, ivabradine is the first antianginal treatment shown to reduce myocardial infarction and revascularisation and to have a good tolerability profile even when used with other drugs.

The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm. In the overall study population treatment with ivabradine did not result in a significant reduction of the primary composite end point Cardiovascular death, admission to hospital for acute MI and admission to hospital for heart failure. Hence the results of BEAUTIFUL constitute a step further in the management of these coronary patients with heart rate above 70 bpm because, for the first time it has been shown that pure heart rate reduction with ivabradine further reduces coronary events even in patients receiving the current optimal cardiovascular therapy.

This study also confirms that ivabradine is safe and well tolerated and can be used with all routinely prescribed cardiovascular drugs. Despite all the advances, the World Health Organisation reports that till coronary artery disease will remain the leading healthcare problem worldwide3. References: 1. Eur Heart J. Our mission: To reduce the burden of cardiovascular disease. All rights reserved.

Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more. Sign in to My ESC. ESC sub specialties communities. Associations Working Groups Councils. Read your latest personalised notifications Sign in No account yet? Don't miss out Read your latest personalised notifications Ok, got it. Loading quicklinks About the ESC. Press and Media. Follow us. Contact us.

DRUM RUDIMENT PDF

BEAUTIFUL TRIAL

Study record managers: refer to the Data Element Definitions if submitting registration or results information. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.

EARIAS VITTELLA PDF

No account yet? Start here. Munich, Germany, 31 August, The results of the much awaited BEAUTIFUL morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction trial have shown that coronary artery disease CAD patients with left ventricular dysfunction LVD and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients heart rate above 70 bpm treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy. With the BEAUTIFUL results, ivabradine is the first antianginal treatment shown to reduce myocardial infarction and revascularisation and to have a good tolerability profile even when used with other drugs. The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm. In the overall study population treatment with ivabradine did not result in a significant reduction of the primary composite end point Cardiovascular death, admission to hospital for acute MI and admission to hospital for heart failure.

Related Articles